Utilizing MCID for evaluating clinical relevance of AD therapeutic interventions
Abstract With the recent approval of disease‐modifying treatments for mild cognitive impairment (MCI) and mild Alzheimer's disease (AD) by the United States Food and Drug Administration (FDA), Medicines and Healthcare products Regulatory Agency (MHRA), European Medicine Agency's Committee for Medici...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wiley
2025-07-01
|
| Edice: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Témata: | |
| On-line přístup: | https://doi.org/10.1002/trc2.70138 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|